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Abstract
Dendritic cell (DC) activation and antigen presentation are critical for efficient priming of T cell 
responses. Here, we study how lentiviral vectors (LVs) deliver antigen and activate DCs to 
generate T cell immunization in vivo. We report that antigenic proteins delivered in vector 
particles via pseudotransduction were sufficient to stimulate an antigen-specific immune response. 
The delivery of the viral genome encoding the antigen increased the magnitude of this response in 
vivo but was irrelevant in vitro. Activation of DCs by LVs was independent of MyD88, TRIF, and 
MAVS, ruling out an involvement of Toll-like receptor or RIG-I–like receptor signaling. Cellular 
DNA packaged in LV preparations induced DC activation by the host STING (stimulator of 
interferon genes) and cGAS (cyclic guanosine monophosphate–adenosine monophosphate 
synthase) pathway. Envelope-mediated viral fusion also activated DCs in a phosphoinositide 3-
kinase–dependent but STING-independent process. Pseudotransduction, transduction, viral fusion, 
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and delivery of cellular DNA collaborate to make the DC-targeted LV preparation an effective 
immunogen.
INTRODUCTION
Dendritic cells (DCs) are targets for immunization purposes because of their superior ability 
to process antigens and present them to T cells. One strategy uses an HIV-1–derived 
lentiviral vector (LV) to deliver genes encoding antigen to DCs by pseudotyping the vector 
with a mutant DC-targeting Sindbis virus glycoprotein (SVGmu) (1, 2). The in vivo 
administration of this LV resulted in the selective expression of antigen in DCs and efficient 
priming of antigen-specific CD8+ T cells with antitumor immunity in mice in comparison 
with methods using recombinant protein antigen or adoptive transfer of antigen-loaded or 
viral vector–transduced DCs. DC-targeted LV vaccines are under clinical evaluation in 
humans (3). However, the exact mechanism behind such immunization is unclear. It is 
evident that antigen delivery methods lacking a DC maturation signal—such as antigen 
conjugated to the DC-specific anti–DEC-205 antibody—led to effective antigen presentation 
but promoted tolerance rather than immunity (4, 5). The coadministration of a maturation 
stimulus was required to break immune tolerance (4). Thus, the efficacy of DC-targeted LV 
immunization likely requires the coupling of two independent functions: delivery of antigen 
and activation of DCs.
The first function—LV antigen delivery to DCs—is thought to primarily occur by 
transduction, which requires overcoming host restriction factors such as SAMHD-1 that 
block reverse transcription (6). Barriers to transduction are surmountable by using precursor 
DCs, high multiplicity of infection (MOI), or codelivering Vpx (7–10). Other mechanisms 
may enable delivery of protein antigens to DCs independent of transduction.
The second function—LV activation of DCs—can occur in well-differentiated DCs and with 
high MOI (7, 8, 11). LV nucleic acids can be detected by intracellular pathways involving 
endosomal Toll-like receptors (TLRs) (12–14), mitochondrial antiviral-signaling protein 
(MAVS) (15), cyclic guanosine monophosphate–adenosine monophosphate synthase 
(cGAS), and stimulator of interferon genes (STING) (16–18). However, lentivirus-like 
particles, which were deficient of viral nucleic acids, elicited potent antigen-specific CD8+ T 
cells responses, suggesting that vector components other than viral nucleic acids contribute 
to DC activation (19–21).
In this study, we report that LV pseudotransduction was a key mechanism of antigen delivery 
and immune stimulation. LV transduction contributed to antigen delivery in vivo but was not 
required for immune stimulation. LVs induced DC activation via two processes. First, viral 
envelope–mediated fusion itself induced a phosphoinositide 3-kinase (PI3K)–dependent and 
STING-independent pathway. Second, we find that the human genomic DNA within virion 
preparations activated the STING and cGAS pathway.
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RESULTS
LV pseudotransduction activates DCs
We first sought to understand the mechanism of antigen delivery to DCs generated at day 8 
of culture with LV encoding green fluorescent protein (GFP) pseudotyped with vesicular 
stomatitis virus glycoprotein (VSV-G) or SVGmu (1). Culture of mouse bone marrow cells 
in granulocyte-macrophage colony-stimulating factor (GM-CSF) generated a heterogeneous 
population of which 70% were well-differentiated bone marrow–derived DCs (BMDCs) 
based on the expression of CD11c and CD11b (fig. S1A). Human monocytes cultured in 
GM-CSF and interleukin-4 (IL-4) generated a cell population composed of 96% monocyte-
derived DCs (moDCs) based on negative expression of CD14 and positive expression of DC-
SIGN (fig. S1B). Well-differentiated mouse BMDCs and human moDCs were difficult to 
transduce in vitro, but up to an eightfold increase in GFP mean fluorescence intensity (MFI) 
was observed [Fig 1, A (top) and B (left)] and undiminished by reverse transcriptase 
inhibitors (RTIs) [Fig 1, C (top) and D]. By contrast, 293T cells treated with the same dose 
of LVs were efficiently transduced with up to a 21-fold increase in GFP MFI in a process 
that was sensitive to RTIs [Fig 1, C (top right) and D (right)]. The GFP expression in 
BMDCs was dependent on the dose of LVs but not on whether the LVs were from 
unconcentrated or concentrated preparations (fig. S2A). In addition, GFP expression in 
BMDCs was highest immediately after LV treatment and then steadily decreased over 48 
hours (Fig 1B, left). Although LVs can deliver host cellular mRNA (22), we found that the 
protein synthesis inhibitor cycloheximide failed to decrease BMDC expression of GFP (Fig 
1E), suggesting that the GFP was not produced de novo in DCs. We could detect GFP in 
lysates of LV particles by Western blot analysis (Fig 1F), finding about 1.53 μg of GFP per 
microgram of p24 by enzyme-linked immunosorbent assay (ELISA). These results are 
consistent with previous reports that LVs were capable of pseudotransduction (23, 24).
We next sought to determine whether LV pseudotransduction was important to DC 
activation. Consistent with previous work, we found that mouse BMDCs were activated by 
LVs, as demonstrated by the increase expression of activation markers CD86 and major 
histocompatibility complex II (MHC II) molecule and secretion of cytokines IL-6 and 
IL-12/23 [Fig 1, A (middle and bottom), B (middle and right), and G] (1, 14) in a dose-
dependent manner (fig. S2B). DC activation was similar between unconcentrated and 
concentrated LV preparations (fig. S2B). Pseudotransduction occurred in both well- and 
less-differentiated BMDCs (fig. S3A), but LV activation occurred only among the well-
differentiated DCs (fig. S3B). LV activation of mouse BMDCs and human moDCs was not 
diminished by RTIs [Fig 1, C (bottom), H, and I], suggesting that LVs activated DCs via a 
reverse transcriptase–independent mechanism. This lack of sensitivity to RTIs was not due 
to ineffective inhibition of reverse transcription because the RTIs blocked GFP transduction 
in LV-infected 293T cells [Fig 1, C (top right) and D (right)].
To determine the LV component responsible for DC activation, we generated a platform of 
genome-less virus-like particles (VLPs) by omitting plasmids encoding the viral genome, 
capsid, or envelope (Fig 2A) (13, 25). We confirmed the presence of the viral envelope and 
capsid by detecting VSV-G and p24, respectively, using Western blot analysis (Fig 2B). 
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Similar to LVs, we found that pseudotyped VLPs incorporated the vector-encoded proteins 
GFP or ovalbumin (OVA) but not “bald” viral particles that were produced by transfecting 
293T cells with only the packaging plasmids encoding gag, pol, and rev. To assess whether 
these proteins were carried within the vectors or associated externally, we treated LV and 
VLPs incorporating OVA with proteinase K, inactivated the proteinase K with phenyl-
methylsulfonyl fluoride (PMSF), lysed the vectors, and still detected OVA in the lysate, 
indicating that the OVA in vectors was proteinase K–resistant and thus carried within 
particles (Fig 2C). An OVA suspension, which was not associated with vectors, was not 
proteinase K–resistant. We next found that the pseudotyped VLPs but not “bald” VLPs 
delivered GFP and induced the activation of mouse BMDCs (Fig 2, D and E). The inclusion 
of the vector genome or viral capsid into the VLP had no effect on BMDC activation [Fig 2, 
D (middle and right) and E]. Furthermore, VSV-G–pseudotyped VLPs capably delivered 
GFP and activated human moDCs (Fig 2F). Together, these data suggest that the viral 
envelope, but not the vector genome or capsid, was necessary and sufficient to activate DCs.
LV genome, cDNA, and capsid are not adjuvants in vivo
To determine whether these findings were relevant in vivo, we injected into mice the DC-
targeted SVGmu-pseudotyped LV-OVA with or without a concurrent oral regimen of RTIs or 
VLP carrying OVA pseudotyped with SVGmu (VLP-OVA). We initially found that OVA-
specific CD8+ T cells were similarly induced in all three groups at 7 days after 
immunization (Fig 3A and fig. S1C). However, through 10 days after immunization, the 
magnitude of these cells continued to increase in LV-immunized mice but not in mice 
immunized with LV-OVA with RTIs or VLP (Fig 3A), suggesting that transduction was 
enhanced, but was not necessary, for inducing antigen-specific CD8+ T cells. After the 
second administration of homologous vector, the OVA-specific CD8+ T cells were boosted 
in all three groups (Fig 3A, right) and expressed similar effector memory phenotypes 
(CD62LloCD44hi) (Fig 3B). After the secondary immune responses subsided, we injected 5 
× 106 OVA-expressing E.G7 thymoma tumor cells and 5 × 106 control non–OVA-expressing 
EL4 thymoma tumor cells on opposing legs, enabling intra-animal comparison. Mice 
homologously prime- boosted with LV with or without RTIs or VLPs were protected against 
the growth of OVA-expressing E.G7 tumors (Fig 3C, left). As expected, non–OVA-
expressing EL4 tumors continued to grow in the immunized mice (Fig 3C, right). The 
antitumor protection of mice immunized with LV with RTI and VLP was not altogether 
unexpected because 8 to 10% of the CD8+ T cells were OVA-specific after the boost. The 
similar immunization responses of mice receiving LV with RTIs and VLP demonstrate that a 
component of LV immunization was independent of reverse transcription and the viral 
genome, likely due to pseudotransduction. We next found that immunization responses were 
similar between mice homologously prime-boosted with VLPs carrying OVA with or 
without the viral capsid (VLP-OVA or VLP-OVAΔgag, respectively) (Fig 3, D and E). 
Therefore, VLPs, which had the viral envelope as the sole viral component, generated a 
strong-enough memory CD8+ T cell response to be protective against the growth of OVA-
expressing E.G7 tumor cells (Fig 3F). The viral capsid did not enhance immunization 
responses.
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We next questioned why LV-immunized mice had a greater immune response compared with 
mice treated with LV with RTI or VLP. We generated an SVGmu-pseudotyped LV encoding 
GFP and carrying the protein OVA (LV-GFPgene-OVAprotein). Because the vector-generated 
LV DNA did not encode OVA, we could assess whether LV DNA enhances OVA 
pseudotransduction. This vector induced an OVA-specific CD8+ T cell response similar to 
VLP-immunized mice but not LV-immunized mice, suggesting that reverse-transcribed LV 
DNA did not enhance the antigen-specific CD8+ T cell response produced by 
pseudotransduction (Fig 3G). Together, these results suggest that LV genome transduction 
amplified antigen delivery but not immune stimulation in vivo.
The direct injection of SVGmu-pseudotyped LV into mice specifically transduces 
conventional DCs (cDCs) in vivo and not other immune cells (1, 26, 27). To assess whether 
DCs were pseudotransduced in vivo, we subcutaneously injected SVGmu-pseudotyped VLP 
carrying GFP into the hindleg of wild-type mice and, after 1 day, harvested lymphoid tissue 
to analyze cells for GFP expression. GFP-positive cells were detected in cDCs, particularly 
in the CD11b− and CD11b+ cDC subsets, from the draining inguinal lymph nodes of VLP-
immunized mice but not of unimmunized mice (figs. S1D and S4A). There was no obvious 
difference in GFP expression among the plasmacytoid DCs, B cells, T cells, or macrophages 
isolated from the lymph nodes of VLP-immunized and unimmunized mice (fig. S4). These 
results suggest that the DC-targeted vectors pseudotransduced cDCs in vivo.
LVs and VLPs activate DCs and adaptive immunity via the STING and cGAS pathway
We next set out to identify the innate immune signaling pathway responsible for LV 
detection. LVs capably activated BMDCs from mice deficient in MyD88, TRIF, or MAVS 
(Fig 4A). Activation of BMDCs from mice doubly deficient in MyD88 and TRIF or MyD88 
and MAVS was still unaffected (Fig 4B). LV-OVA immunization of MyD88-, TRIF-, or 
MAVS-deficient mice capably induced OVA-specific effector memory CD8+ T cells (Fig 4, 
C and D). LV-OVA immunization of TLR4-deficient mice was also efficient (fig. S5, A to 
C). In addition, LVs capably activated BMDCs from mice lacking the interferon-α/β (IFN-
α/β) receptor function (fig. S5D), indicating that type I IFN signaling was not required. We 
then turned to the STING and cGAS pathway and found that LV immunization was 
significantly decreased up to threefold in these mutant mice (Fig 4, E and F), suggesting that 
STING and cGAS were important to LV immunization.
In addition, we observed that VLP activation of BMDCs was partially dependent on STING 
and cGAS (Fig 5, A and B). STING- or cGAS-deficient BMDCs treated with VLP carrying 
OVA had a reduced ability to up-regulate the activation marker CD69 on CD8+ T cells 
expressing an OVA-specific T cell receptor (Fig 5, C and D, and fig. S1E). The homologous 
prime-boost vaccination of STING- or cGAS-deficient mice with the DC-targeted VLP-OVA 
induced up to threefold less effector memory CD8+ T cells (Fig 5, E to H). Mice deficient in 
MyD88 (28), TRIF (29), MAVS (30), type I IFN receptor (31), STING (32), or cGAS (33) 
are born at expected Mendelian ratios and grow without obvious developmental or fertility 
issues. BMDC populations generated in vitro among these mutants were represented 
similarly compared with wild-type BMDCs (fig. S6). Together, these results suggest that a 
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component within LVs, which is not the viral genome, triggered the host STING and cGAS 
pathway.
Viral fusion is required for DC activation
VSV and Sindbis virus release viral contents into the cytosol through pH-dependent fusion 
between the viral envelope and the host endosomal membrane (34, 35). LV and VLP 
activation of BMDCs was abolished in the presence of chloroquine, an inhibitor of 
endosomal acidification and viral fusion (Fig 6A). This effect was not due to lack of vector 
internalization into endosomes because intracellular punctate GFP was evident in LV- and 
VLP-treated cells receiving chloroquine by microscopy (Fig 6B). We also generated vectors 
pseudotyped with an altered VSV-G, in which mutations rendered the envelope fusion-
defective without affecting envelope binding or receptor-mediated endocytosis (36). BMDCs 
treated with fusion-defective VLP showed punctate GFP presence similar to VLP- and 
chloroquine-treated cells, whereas BMDCs treated with fusion-competent VLP displayed 
diffuse intracellular GFP presence (Fig 6B). The fusion-defective LV and VLP failed to 
activate mouse BMDCs (Fig 6C), suggesting that viral fusion was required for the activation 
of DCs.
We next asked whether the viral process of membrane fusion itself and/or the release of a 
putative activating component into the cytosol represented the activating stimuli. We 
incorporated VSV-G into the lipid membrane of noncationic multilamellar liposomes, which 
allowed for the liposomal contents to evade lysosomal degradation and be delivered into the 
cytosol via viral envelope–directed fusion (37). The delivery of GFP and activation of mouse 
BMDCs were greatly enhanced if the liposomes were enveloped with VSV-G (Fig 6D), 
indicating that VSV-G–directed fusion itself was immunostimulatory. DC activation was 
unaffected in STING-deficient mouse BMDCs treated with VSV-G liposomes (Fig 6E), 
which suggests that VSV-G–directed fusion induced DC activation independent of STING.
We next examined the role of PI3K in VSV-G fusion–induced DC activation given its role in 
viral fusion and DC activation (38). We found that DC activation by VSV-G–pseudotyped 
VLP was, in part, inhibited by the PI3K inhibitor, LY292004 (Fig 6F). In addition, we 
observed that VSV-G–pseudotyped VLPs were capable of inducing phosphorylation of PI3K 
but not fusion-defective VLPs (fig. S7A). VSV-G–pseudotyped LVs capably transduced 
293T cells treated in the presence of LY292004 (fig. S7B), which is consistent with previous 
work demonstrating that the entry and fusion of VSV- G–pseudotyped vectors are PI3K-
independent (39, 40). Thus, these results suggest that activation of PI3K occurred 
downstream of viral fusion. To assess whether STING or cGAS was involved in this fusion- 
induced PI3K-dependent pathway, we treated BMDCs from mice deficient in STING or 
cGAS with VSV-G–pseudotyped VLPs in the presence of LY292004. Activation was 
partially decreased in the VLP- treated STING-deficient BMDCs and then further decreased 
with the addition of LY292004 (Fig 6G), suggesting that the VSV-G fusion and PI3K-
dependent pathway were largely independent of STING and cGAS. Together, these data 
suggest that there are two pathways contributing to VLP activation of DCs: one that is 
fusion- and PI3K-dependent and one that is STING- and cGAS-dependent.
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Human genomic DNA carried by lentiviral particles and VLPs is immunostimulatory
We next sought to identify the stimulatory viral component that was released into the 
cytoplasm by viral fusion and was responsible for activating STING and cGAS. We 
amplified plasmid-specific and human genomic DNA sequences from the vector 
preparations (Fig 7A) (13). We did not find evidence of human DNA in cell-free supernatant 
collected from 293T cells transfected with a mock plasmid. To assess whether the DNA was 
carried within or associated externally to the particles, we pretreated VLPs with 
deoxyribonuclease I (DNase I) to degrade external DNA and then inactivated DNase I with 
EDTA before the particles were lysed and then analyzed by polymerase chain reaction 
(PCR). Despite pretreatment with DNase I, we continued to detect plasmid and human DNA 
in the vector preparations, suggesting that this DNA was contained within the particles (Fig 
7B). We used genomic DNA to show that DNase I digestion and EDTA inactivation were 
effective (Fig 7C). In addition, we detected about 150 ng of double-stranded DNA (dsDNA) 
per microliter and 12 ng of single-stranded DNA per microliter of the concentrated LV 
preparation (fig. S8A). The DNA extracted from the vector preparation appeared to be 
mostly composed of fragments of less than 10 kb, whereas genomic DNA extracted from 
cells was of longer fragments greater than 10 kb (fig. S8B). Deep sequencing of the DNA 
extracted from the viral particles demonstrated that about 99% of the reads were mapped to 
the human genome, whereas about only 1% of the reads were mapped to plasmid DNA (fig. 
S8C). Of the reads that were mapped to the human genome, there appeared to be a random 
distribution across the human chromosomes (fig. S8D). These results suggest that the DNA 
within LV preparations was predominantly double-stranded, fragmented, human genomic in 
origin, and incorporated into the viral particles randomly.
We also amplified plasmid and human DNA in HIV-1 produced from 293T cell transfection 
(Fig 7D). To determine whether the presence of genomic DNA in vector particles was 
particular to the transfection process, we passaged HIV-1 in human peripheral blood 
mononuclear cells (PBMCs) and amplified human DNA from the cell-free HIV-1 
supernatant (Fig 7E). Human DNA was not detected in the cell-free supernatant collected 
from uninfected PBMCs. In addition, some of the DNA detected in the passaged cell-free 
HIV-1 supernatant was resistant to DNase I (Fig 7F), suggesting that human genomic DNA 
was also encapsulated inside HIV-1 particles.
We next questioned whether the delivery of plasmid or genomic DNA by viral fusion would 
enhance the DC activation generated by viral fusion itself. We treated mouse BMDCs with 
empty VSV-G liposomes or VSV-G liposomes carrying intact plasmid DNA or genomic 
DNA extracted from 293T cells. Human genomic DNA enhanced the immunogenicity of the 
fusogenic liposomes in wild-type BMDCs (Fig 7G), which was abrogated in STING-
deficient BMDCs (Fig 7H). The addition of intact plasmid DNA to fusogenic liposomes did 
not enhance BMDC activation (Fig 7G). Furthermore, LVs generated by either transient 
transfection using plasmids or plasmid-free packaging system similarly stimulated wild-type 
BMDCs (Fig 7I), suggesting that plasmid DNA within the vector preparations was not likely 
a dominant activator of DCs. LVs generated by plasmid DNA–free cell lines capably 
stimulate innate and adaptive immune responses in vivo (41, 42). These findings provide an 
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explanation for the STING and cGAS dependence observed in the innate and adaptive 
immune responses generated by LVs and VLPs.
DISCUSSION
In the present investigation, we found that vector-encoded protein antigen carried by vector 
particles via pseudotransduction sufficiently delivered antigen and stimulated the immune 
system. LV transduction was not inherently immunostimulatory but contributed to antigen 
delivery. Viral envelope–mediated fusion itself induced DC activation in a PI3K-dependent 
but STING- and type I IFN signaling–independent manner. Last, cellular DNA packaged 
from producer cells carried by particles activated the host STING and cGAS pathway.
Our results suggest that DCs were pseudotransduced in vivo and capable of stimulating 
antigen-specific immunity. Because of the transient and relatively low amount of antigen 
delivered compared with LV transduction, pseudotransduction has been considered an 
artifact (23, 24), and LV transduction has been considered the underlying mechanism of 
antigen delivery and immune stimulation (1, 9, 14, 43). However, we found that reverse-
transcribed LV DNA was not inherently immunostimulatory in vivo but contributed to 
antigen delivery. This is consistent with our in vitro results showing that virtually all of the 
antigenic stimulation of DCs was due to pseudotransduction because activation was 
insensitive to RTIs and efficiently occurred with genome-deficient vectors. Neither the dual 
mechanisms of transduction and pseudotransduction nor the powerful role of 
pseudotransduction for delivering antigen and activating DCs in vivo has been appreciated. 
In this study, we presume that transducing and pseudotransducing particles contain the 
vector-encoded protein, but separation of these particles by size or density has been proven 
difficult.
Viral fusion by herpes VLPs has been found to activate DCs in a STING-dependent manner 
(38). We found that DC activation was, in part, a consequence of fusion induced between the 
vector and endosomal membranes but in a STING-independent manner. Furthermore, PI3K 
signaling was activated downstream of VSV-G viral fusion because fusion-defective VLPs 
failed to activate PI3K and LV fusion and transduction was PI3K-independent (39, 40). In 
contrast, herpes entry and fusion are regulated by PI3K (44–47). Although PI3K is important 
in VSV-mediated type I IFN production via TLR4 (48), we did not find whether type I IFN 
or TLR4 signaling was required for LV-mediated DC activation or immunization. How PI3K 
is activated by VSV-G–mediated viral fusion and whether there are intermediary signaling 
molecules remain unknown.
We identified cellular DNA packaged from producer cells and carried by vector particles as 
the dominant activator of the STING and cGAS pathway. Nonviral DNA such as plasmid 
DNA has been found in LV particles and reported to activate plasmacytoid DCs in an 
MyD88-dependent manner (13). However, the vast majority of DNA in our LV preparations 
was human genomic DNA. Further, LVs generated by plasmid-free cell lines capably 
activated immune responses (41, 42). We did not examine plasmacytoid DCs because type I 
IFN signaling was not required for DC activation and pseudotransduction of plasmacytoid 
DCs was not detected in vivo. We assume that vector- encoded proteins such as GFP and 
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OVA were merely encapsulated cytoplasm in the particles, but how genomic DNA is 
packaged within particles will require further investigation. HIV infection induces cell death 
by pyroptosis, a process that leads to DNA fragmentation (49). It could be that HIV particles 
pick up random fragmented DNA from the infected host cell. However, the formation of 
vector particles by transfection does not typically induce pyroptosis. Liposomal transfection 
reagents are added to dividing cells and may induce host DNA damage and increase 
cytosolic dsDNA in cells (50). Therefore, fragmented, cytoplasmic genomic DNA may be 
available for encapsulation in various cell types via different processes. We found that the 
human genomic DNA detected in our LV preparation randomly represented the human 
chromosomes. In addition, viral particles generated from at least two cell types packaged 
genomic DNA. Whether the incorporation of genomic DNA into vector particles extends to 
other viruses generated from different cell types remains to be determined.
In conclusion, we identify several important mechanisms involved in DC-targeted LV 
immunization. We highlight the importance of LV pseudotransduction as a mechanism of 
antigen delivery and immune stimulation in vivo. Our results suggest that viral fusion itself 
induces a PI3K-dependent, STING-independent process. In addition, the delivery of cellular 
DNA by viral particles activates the host STING and cGAS pathway. The development of 
DNA adjuvants as STING and cGAS agonists could provide new therapeutic strategies for 
vaccination.
MATERIALS AND METHODS
Study design
This study began as an investigation of understanding how LVs deliver antigen to DCs and 
provide immune stimulation. For this purpose, we used DCs in vitro and administered in 
vivo DC-targeted LVs to mice to study the effects of LV on DCs. We used various 
mechanistic studies involving VLPs and transgenic mice to determine the vector component 
and intracellular signaling pathway important to elicit DC activation. In mouse experiments, 
littermate comparisons were used when possible. All mice between 6 and 12 weeks of age 
were used with sex- and age-matched controls. The investigators were not blinded. In mouse 
experiments involving tumor injections, mice were euthanized when the tumor size reached 
200 mm2. Experimental replication is indicated in the figure legends.
Mice
C57BL/6J, MyD88−/−, C57BL/6J-Ticam1Lps2, Tmem173−/−, C57BL/6- 
Tg(TcraTcrb)1100Mjb/J (the Jackson Laboratory), MAVS−/− (G. Cheng), and cGAS−/− (Z. 
Chen) mice were maintained on the C57BL/6J background and used according to the 
protocols approved by the Institutional Animal Care and Use Committee at California 
Institute of Technology (Caltech).
Isolation and culture of DCs
Differentiation of BMDCs was achieved by culture for 8 days in media containing GM-CSF 
(100 ng ml−1) from J558L-conditioned medium (2). Human moDCs were generated by 
culture for 8 days of CD14+ peripheral blood monocytes [University of California, Los 
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Angeles (UCLA) Center for AIDS Research (CFAR) Virology Core Laboratory] in media 
containing human GM-CSF (100 ng ml−1) and IL-4 (50 ng ml−1; PeproTech). DCs were 
cultured in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich), 
1% (v/v) nonessential amino acids (HyClone), 1 mM sodium pyruvate (Gibco), 10 mM 
Hepes (Gibco), and 0.05 mM 2-mercaptoethanol (Gibco). DCs were isolated ex vivo from 
mice using immunomagnetic negative isolation (table S1).
DC treatment with vectors
DCs (1 × 106 to 2 × 106 cells) were centrifuged with vectors at 1050g at 30°C for 90 min 
and with Polybrene (8 μg ml−1). After centrifugation, the supernatant was removed and 
replaced with fresh medium and cytokines and incubated at 37°C with 5% CO2. 
Cycloheximide and chloroquine (Sigma-Aldrich) were added to cell cultures 1 hour before 
vector treatment. Tenofovir and efavirenz [National Institutes of Health (NIH) AIDS 
Reagent Program] were added to cell cultures 6 hours before vector treatment.
Mouse immunization and tumor and RTI treatments
LVs and VLPs were injected subcutaneously into the right flank of mice. Prime-boost 
immunizations contained between 25 and 50 ng of p24. All vectors were normalized to 
equivalent amounts of OVA and/or p24 by ELISA. Unimmunized mice received equal 
volume of injections of phosphate-buffered saline (PBS). Blood samples were lysed with red 
blood cell lysis (BioLegend) before analysis. For the tumor experiments, mice received 5 × 
106 EL4 or E.G7 cells injected subcutaneously into the opposing flanks of the mice. Tumor 
size was measured and shown as a product of the two largest perpendicular diameters a × b 
(in square millimeters). Tablets containing efavirenz (600 mg), emtricitabine (200 mg), and 
tenofovir disoproxil fumarate (300 mg; Cipla) were crushed, resuspended in PBS containing 
1% (v/v) dimethyl sulfoxide, filtered through a 0.22-μm filter, and stored in aliquots at 
−80°C. RTIs were added to the fresh drinking water of mice containing efavirenz (10 mg ml
−1), emtricitabine (3.6 mg ml−1), and tenofovir (5.4 mg ml−1). Fresh water containing RTIs 
was replaced two times a week. Mice receiving no RTIs were given similar volumes of 
drinking water and replaced accordingly. Mice were initiated on RTIs 1 week before 
immunization and continued throughout the duration of the experiment.
In vitro DC stimulation of OT-1 cells
Mouse BMDCs were spin-infected with VLPs carrying OVA, washed, and resuspended in 
fresh media and lipopolysaccharide (LPS; 1 μg ml−1). CD8+ T cells were purified using 
MACS Columns (Miltenyi) from the spleen cells of OT-1 transgenic mice and cultured with 
the uninfected or VLP-infected BMDCs at a ratio of 1:1 and analyzed 24 hours after 
coculture.
Liposomes
Multilamellar liposomes were prepared using dioleoylphosphatidylcholine (DOPC), 
dioleoylphosphatidylglycerol (DOPG), and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[4-(p-maleimidophenyl) butyramide (MPB-PE) (NOF Corporation) 
and were combined in chloroform at a molar lipid ratio of DOPC/DOPG/MPB-PE = 4:1:5, 
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and the organic solvent in the lipid mixture was evaporated under argon gas (51). The lipid 
mixture was further dried under vacuum overnight to form dried thin lipid films. The 
resultant dried film containing 1.12 μg of lipids was hydrated in bis-tris propane (10 mM) at 
pH 7.0 with GFP (STA-201, Cell Biolabs) at a concentration of 125 ng ml−1 in a total 
volume of 300 μl. Polyhistidine-tagged VSV-G was expressed and purified from a 
suspension 293E cells after a 48-hour transfection using Ni-NTA column purification. 
Purified VSV-G protein (200 μg ml−1) was added to the lipid hydration mixture before 
sonication. Alternatively, 5 ml of VSV-G–enveloped VLPs, collected from the medium of 
293T cell transfected with pVSV-G and purified and concentrated as described above, was 
added to the lipid hydration mixture, as previously described (37), and DNA was not 
detectable by PCR in the liposomes made by this method. To add DNA into the liposomes, 
we extracted genomic DNA from 293T cells using a genomic DNA extraction kit (Thermo 
Fisher Scientific) or endotoxin-free intact plasmid DNA generated from Escherichia coli 
cells using a plasmid DNA extraction kit (Qiagen). Genomic or plasmid DNA (10 μg ml−1) 
was added to the lipid hydration mixture. Lipid film and hydration mixture were vigorously 
vortexed every 10 min for 1 hour and then applied with four cycles of 15-s sonication 
(Misonix Microson XL2000) on ice in 1-min intervals for each cycle. To induce divalent-
triggered vesicle fusion, we added MgCl2 (10 mM). The resulting multilamellar vesicles 
were further cross-linked by the addition of dithiothreitol (1.5 mM; Sigma-Aldrich) for 1 
hour at 37°C. The resulting vesicles were collected by centrifugation at 14,000g for 4 min 
and then washed twice with PBS and resuspended in PBS with a final DNA concentration of 
250 ng μl−1.
Statistical analyses
Data were analyzed using GraphPad Prism software (GraphPad Software Inc.). The 
statistical significance of differences for two groups was determined using Student’s t test 
and one-way analysis of variance (ANOVA) for multiple comparisons, as indicated in the 
figure legends.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. LV pseudotransduction delivers proteins and activates DCs
(A) Representative fluorescence-activated cell sorting (FACS) plots of mouse BMDCs that 
were treated with LV-GFP(V), LV-GFP(S), LPS, or no vector (NV) and analyzed for 
expression of GFP, CD86, and I-Ab. GFP geometric MFI was measured immediately after 
LV spin inoculation, and CD86 and I-Ab expression was measured 24 hours after LV 
treatment. (B) GFP, CD86, and I-Ab expression of LV-treated BM-DCs was measured over 
48 hours. (C) Representative FACS plots of mouse BMDCs, human moDCs, and 293T cells 
that were incubated with tenofovir (TFV; 40 μM), efavirenz (EFV; 80 μM), or no drug (ND) 
6 hours before treatment with LV-GFP(V) and then analyzed 24 hours later. (D) Graph 
depicts the GFP MFI of BMDCs, moDCs, and 293T cells from (C). (E) Mouse BMDCs 
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were incubated with or without cycloheximide (CHX; 50 μg ml−1) 1 hour before treatment 
with LV-GFP(V), and then, GFP MFI was presented relative to those BMDCs receiving no 
LV with or without cycloheximide. (F) Western blot analysis of GFP of lysates from LV-
GFP(V) and LV expressing OVA pseudotyped with VSV-G [LV-OVA(V)] and purified GFP 
protein (40 ng). (G) Mouse BMDCs were treated as in (A) and analyzed for the amount of 
IL-6 and IL-12/23 in the supernatant by ELISA 24 hours after LV treatment. (H and I) 
Mouse BMDCs (H) and human moDCs (I) were treated as in (C) and analyzed for 
expression of CD86, I-Ab, or amount of IL-12/23 and/or IL-6 in the supernatant 24 hours 
after LV treatment. Data are representative of two (A to D and G to I) or three (E and F) 
independent experiments. Results are shown as mean ± SEM (B, D, E, G, and H). n.s., not 
significant. P > 0.05; ***P < 0.001 [one-way ANOVA (D and H) and unpaired Student’s t 
test (E and G)].
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Fig. 2. LV envelope is responsible for DC activation
(A) Schematic of components of LV and VLPs. (B) Western blot analysis for GFP, VSV-G, 
and p24 on LV and VLP lysates. (C) Western blot analysis detecting OVA in the lysate of the 
following SVGmu-pseudotyped vectors: LV carrying OVA (LV-OVA), VLP carrying OVA 
(VLP-OVA), and VLP-carrying OVA deficient of gag (VLP-OVAΔgag). Vectors were treated 
or not treated with proteinase K, which was inactivated with PMSF before vector lysis. To 
verify whether proteinase K degradation was effective, we used soluble OVA as a control. (D 
and E) Mouse BMDCs were treated with VSV-G or SVGmu-pseudotyped LVs and VLPs 
and then analyzed at 24 hours for GFP, CD86, and I-Ab expression by flow cytometry (D) 
and for the amount of IL-6 and IL-12/23 in the cell supernatant by ELISA (E). (F) Human 
moDCs were treated with LV-GFP(V) or VLP carrying GFP deficient of gag [VLP-
GFPΔgag(V)] and analyzed at 24 hours for GFP, CD86, and human MHC II molecule 
human lymphocyte antigen-D–related (HLA-DR) expression by flow cytometry. Data are 
representative of three (B and C) or two (D to F) independent experiments. Results are 
shown as mean ± SEM. P > 0.05; **P < 0.005; ***P < 0.001 (unpaired Student’s t test).
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Fig. 3. LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming 
in vivo
(A) Wild-type mice received homologous prime-boost vaccination of SVGmu-pseudotyped 
LV-OVA with or without RTI or VLP-OVA (n = 8 mice per group). Representative FACS 
plots show OVA-tetramer+ cells gated on CD8+ T cells from the blood at 7 and 10 days after 
primary immunization (left). Graph depicts percentages of OVA-tetramer+ CD8+ T cells 
from the blood of immunized and unimmunized mice over time (black arrow, boost) (right). 
(B) Representative FACS plots show expression of CD62L and CD44 on OVA- tetramer+ 
CD8+ T cells from immunized mice compared with naïve CD8+ T cells from unimmunized 
mice at 7 days after boost (left). Graphs depict percentages of CD62Llo and CD44hi OVA-
tetramer+ cells, with each symbol representing an individual mouse and horizontal bar 
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indicating the mean (right). (C) Seven weeks after boost, mice were injected with 5 × 106 
OVA-expressing E.G7 thymoma tumor cells and 5 × 106 EL4 (control) non–OVA-expressing 
EL4 thymoma tumor cells on opposing legs, and tumor sizes were measured. (D to F) Wild-
type mice were homologously prime-boosted with LV-OVA, VLP-OVA, or capsid-less VLP-
OVAΔgag. OVA-tetramer+ cells from the blood were analyzed as in (A) (n = 8 mice per 
group) at 7 days after boost (left) and over time (right) (D). CD62L and CD44 expression of 
OVA-tetramer+ CD8+ T cells from immunized mice compared with naïve CD8+ T cells from 
unimmunized mice at 7 days after boost were measured as in (B) (E). Mice were injected 
with tumor cells, as in (C), and tumor sizes were measured (F). (G) Wild-type mice were 
immunized with LV-OVA, LV encoding OVA carrying GFP (LV-GFPgene-OVAprotein), or 
VLP-OVA (n = 8 mice per group), and OVA-tetramer+ CD8+ T cells from the blood were 
measured over time. Statistical comparisons were made between the LV-GFPgene-
OVAprotein– and VLP-OVA– or LV-OVA–immunized mice. Data are representative of two 
independent experiments (A to G). Results are shown as mean ± SEM (A, C, D, F, and G). P 
> 0.05; **P < 0.005; ***P < 0.001 (unpaired Student’s t test).
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Fig. 4. LV activation of DCs and subsequent CD8+ T cell priming are dependent on STING and 
cGAS but not on MyD88, TRIF, or MAVS
(A and B) BMDCs from mice singly or doubly deficient in MyD88, TRIF, and MAVS were 
treated with LV-GFP(V) or LV-GFP(S) and analyzed at 24 hours for expression of CD86 and 
I-Ab by flow cytometry. (C to F) Mice deficient in MyD88, TRIF, MAVS, STING, or cGAS 
were immunized with LV-OVA. Unimmunized wild-type (WT) mice were injected with 
PBS. OVA-tetramer+ cells gated on CD8+ T cells from the blood were demonstrated on 
representative FACS plot at 10 days after primary immunization (C) or measured over time 
(D to F) (left). Statistical comparisons were made between the OVA-tetramer+ CD8+ T cell 
response of the LV-immunized wild-type mice and that of the LV-immunized mutant mice. 
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CD62Llo and CD44hi OVA-tetramer+ CD8+ T cells from LV-immunized mutant and wild-
type mice were compared with naïve CD8+ T cells from unimmunized mice at 10 days on 
representative FACS plots (D to F) (middle) or by group with each symbol representing an 
individual mouse and horizontal bar indicating the mean (D to F) (right). n = 6 mutant 
immunized mice per group; n = 4 wild-type immunized and unimmunized mice per group 
(C and D). n = 6 mice in Tmem173−/− immunized and unimmunized wild-type groups; n = 
10 mice in wild-type immunized group (E). n = 8 per group (F). Data are representative of 
three (A and B) or two (C to E) independent experiments or pooled from two independent 
experiments (F). Results are shown as mean ± SEM (A, B, and D to F). P > 0.05; *P < 0.05; 
**P < 0.005 [one way-ANOVA (A, B, and D) and unpaired Student’s t test (E and F)].
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Fig. 5. VLPs activate DCs and antigen-specific CD8+ T cells via the STING and cGAS pathway
(A and B) BMDCs from Tmem173−/− and cGAS−/− mice were treated with VLP-GFP(V) or 
VLP-GFP(S) and analyzed at 24 hours for CD86 and I-Ab expression by flow cytometry. (C 
and D) Tmem173−/− and cGAS−/− BMDCs were treated with VLP-OVA pseudotyped with 
VSV-G [VLP-OVA(V)] or SVGmu [VLP-OVA(S)] and then cocultured with OT-1 CD8+ T 
cells for 24 hours. Representative FACS plots show expression of the T cell activation 
marker CD69 among the OT-1 CD8+ T cells (C and D) (left). Graph depicts CD69 MFI of 
the OT-1 CD8+ T cells (C and D) (right). (E to H) Tmem173−/−, cGAS−/−, and wild-type 
mice were homologously prime-boosted with SVGmu-pseudotyped VLP-OVA (n = 8 per 
group). OVA-tetramer+ cells gated on CD8+ T cells from the blood were demonstrated on 
representative FACS plot at 10 days after primary immunization (E and G) (left) or 
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measured over time (E and G) (right) (black arrow, boost). Statistical comparisons were 
made between the OVA-tetramer+ CD8+ T cell response of the VLP-immunized wild-type 
and VLP-immunized mutant mice. CD62Llo and CD44hi OVA-tetramer+ CD8+ T cells from 
LV- immunized Tmem173−/−, cGAS−/−, and wild-type mice were compared with naïve 
CD8+ T cells from unimmunized wild-type mice at 10 days on representative FACS plots (F 
and H) (left) or by group with each symbol representing an individual mouse and horizontal 
bar indicating the mean (F and H) (right). Data are representative of two independent 
experiments (A to H). Results are shown as mean ± SEM (A to E and G). P > 0.05; *P < 
0.05; **P < 0.005; ***P < 0.001 (unpaired Student’s t test).
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Fig. 6. Viral fusion is required for DC activation
(A) BMDCs from wild-type mice were incubated with chloroquine (CQ) at 25, 75, 100 μM 
(wedges) or with no drug 1 hour before treatment with LV or VLPs and analyzed at 24 hours 
for CD86 and I-Ab expression by flow cytometry. (B) Fluorescence microscopy was used to 
analyze GFP expression in wild-type mouse BMDCs treated with fusion-competent VLP-
GFP(V) with or without chloroquine (100 μM) or the fusion-defective VLP, VLP-
GFP(V.FD). Magnification, ×400. Scale bars, 10 μm. (C) Wild-type mouse BMDCs were 
treated with fusion-competent or fusion-defective LVs or VLPs carrying GFP and analyzed 
for CD86 and I-Ab expression by flow cytometry. (D and E) BMDCs from wild-type and 
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Tmem173−/− mice were treated with naked (Lipo) or VSV-G–enveloped multilamellar 
liposomes [Lipo(V)] carrying GFP and analyzed at 24 hours for CD86 and I-Ab expression 
by flow cytometry. (F) Wild-type mouse BMDCs were treated with VSV-G– or SVGmu-
pseudotyped VLPs with or without LY292004 (50 μM) and analyzed for CD86 expression 
by flow cytometry and for the amount of IL-12/23 and IL-6 in the supernatant by ELISA. 
(G) BMDCs from Tmem173−/−, cGAS−/−, and wild-type mice were treated with VSV-G–
pseudotyped VLP or LPS (100 ng ml−1) with or without LY292004 (50 μM) and analyzed 
for CD86 expression by flow cytometry. Data are representative of three independent 
experiments (A to D) or two independent experiments (E to G). Results are shown as mean ± 
SEM (A and C to G). P > 0.05; *P < 0.05; **P < 0.005; ***P < 0.001 [one way-ANOVA (C 
and G) and unpaired Student’s t test (D to F)].
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Fig. 7. LV particles and VLPs contain human genomic DNA recognized by the host STING 
pathway
(A) PCR analysis of amplicons of human β-actin (ACTB) and the ampicillin resistance gene 
(amp) detected in the LV and VLP preparations by PCR. The cell-free supernatant collected 
from 293T cells transiently transfected with mock plasmid puc19 was used as a negative 
control. bp, base pairs. (B and C) Amplicons of human Alu element (Alu), ACTB, and VSV-
G (VSIVgp4) (lane 1) were analyzed from VLP preparations (B) or genomic DNA (gDNA) 
(C). VLP preparations and genomic DNA were treated with lysis buffer in the presence of 
DNase I, leading to DNA degradation (lane 2). DNase I was inactivated with EDTA before 
lysis treatment (lane 3). DNase I was inactivated with EDTA, and then, VLP lysate or 
genomic DNA added to show DNase I was effectively inactivated (lane 4). (D) Amplicons of 
ACTB, Alu, and amp were analyzed on HIV-1 supernatant collected from 293T cells 
transiently transfected with the plasmid encoding infectious HIV-1 or 293T genomic DNA. 
(E) HIV-1 was passaged in primary PBMCs, and the cell-free supernatant was collected and 
analyzed for human ACTB by PCR. As a negative control, cell-free supernatant was 
collected from uninfected PBMCs. (F) Supernatant primary PBMCs passaged with HIV-1 
were treated as in (B) and (C). (G and H) BMDCs from wild-type mice were treated with 
naked (Lipo) or VSV-G–enveloped multilamellar liposomes carrying plasmid DNA [Lipo-
plasmid(V)], genomic DNA extracted from 293T cells [Lipo-gDNA(V)], or nothing 
[Lipo(V)] (G). BMDCs from Tmem173−/− or wild-type mice were treated with naked (Lipo) 
or VSV-G–enveloped multilamellar liposomes carrying plasmid DNA [Lipo-plasmid(V)], 
genomic DNA extracted from 293T cells [Lipo-gDNA(V)], or nothing [Lipo(V)] (H). Cells 
were analyzed 24 hours after treatment for CD86 and I-Ab expression by flow cytometry. (I) 
Wild-type mouse BMDCs were treated with LV generated from transient transfection or 
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plasmid-free stable cell line and analyzed for CD86 expression by flow cytometry and for 
the amount of IL-12/23 and IL-6 in the supernatant by ELISA. Data are representative of 
three (A to F) or two (G to I) independent experiments. Results are shown as mean ± SEM 
(G to I). P > 0.05; *P < 0.05; **P < 0.005 (unpaired Student’s t test).
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